Programs

Presentations and Publications

Recent Presentations and Publications | Voxelotor Safety and Efficacy | Voxelotor Mechanism of Action | Selected Key Sickle Cell Disease ResearchSelected Key Transcranial Doppler ResearchAdditional Sickle Cell Disease Research



Voxelotor Mechanism of Action

GBT440 Reverses Sickling of Sickled Red Blood Cells Under Hypoxic Conditions In Vitro
Hematology Reports, Dufu K. and Oksenberg, D., May 2018

Efficacy of GBT440 to left-shift the oxy-hemoglobin dissociation curve in healthy individuals and preserve arterial saturation during submaximal hypoxic exercise
American Thoracic Society International Conference, Stewart et al, May 2018

Effect of GBT440, an R-state stabilizer of hemoglobin, on hypoxic maximal exercise
American Thoracic Society International Conference, Stewart et al, May 2018

GBT440 Improves Red Blood Cell Deformability and Reduces Viscosity of Sickle Cell Blood Under Deoxygenated Conditions
Clinical Hemorheology and Microcirculation, Dufu et al, April 2018

Voxelotor (GBT440), a First‐in‐Class Hemoglobin Oxygen‐affinity Modulator, Has Promising and Reassuring Preclinical and Clinical Data
American Journal of Hematology, Estepp, J., January 2018

GBT1118 Diminishes Vaso-Occlusion in Sickle Cell Disease Mice
59th American Society of Hematology Annual Meeting & Exposition, Alt et al, December 2017

Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin
ACS Medicinal Chemistry Letters, Metcalf et al, January 2017

GBT440 Inhibits Sickling of Sickle Cell Trait Blood Under In Vitro Conditions Mimicking Strenuous Exercise
Hematology Reports, Dufu et al, September 2016

GBT440, a Novel Sickle Haemoglobin Polymerisation Inhibitor, Increases Haemoglobin Oxygen Affinity and Results in a Rapid Improvement in Haemolysis and Anaemia
European Medical Journal, Telfer et al, July 2016

GBT440 Increases Haemoglobin Oxygen Affinity, Reduces Sickling and Prolongs RBC Half‐Life in a Murine Model of Sickle Cell Disease
British Journal of Haematology, Oksenberg et al, July 2016

GBT440 Demonstrates High Specificity for Red Blood Cells in Nonclinical Species
57th American Society of Hematology Annual Meeting & Exposition, Hutchaleelaha et al, December 2015

GTx011, a Potent Allosteric Modifier of Hemoglobin Oxygen Affinity, Prevents RBC Sickling in Whole Blood and Prolongs RBC Half-Life in Vivo in a Murine Model of Sickle Cell Disease
56th American Society of Hematology Annual Meeting & Exposition, Dufu et al, December 2014

GTx011, an Anti-Sickling Compound, Improves SS Blood Rheology By Reduction of HbS polymerization Via Allosteric Modulation of O2 Affinity
56th American Society of Hematology Annual Meeting & Exposition, Patel et al, December 2014

GTx011, a Potent Allosteric Modifier of Hemoglobin Oxygen Affinity, Delays Polymerization and Prevents Sickling
55th American Society of Hematology Annual Meeting & Exposition, Dufu et al, December 2013

GTx011, a Novel Agent that Improves Rheological Properties of Sickle Cell Blood by Increasing Oxygen Affinity for Hemoglobin
55th American Society of Hematology Annual Meeting & Exposition, Patel et al, December 2013